(Photo Credit - Marcum MicroCap)
James S. Manuso, Ph.D., the CEO of RespireRX Pharmaceuticals Inc. (OTC:RSPI), will be reviewing the company's Phase-3 ready dronabinol (synthetic Delta-9-THC) medicine for the treatment of obstructive sleep apnea and more at the Marcum MicroCap Conference today.
As we covered in the article linked above, dronabinol is a lab-made replica of the delta-9-THC cannabinoid that is naturally occurring in marijuana. Since the '80's, dronabinol capsules have been approved by the FDA for treating appetite loss associated with AIDS as well as for nausea and vomiting associated with chemotherapy cancer treatment.
RespireRX plans to get FDA approval for obstructive sleep apnea, a.k.a. OSA. This afflicts millions of americans and could be a huge market.
When & Where
The presentation will be at 10:00 AM EST on June 16th. For those attending the Marcum MicroCap event, presentations will be held at the Grand Hyatt Hotel in Manhattan. For those interested in watching this presentation that are unable to attend the event, Dr. Manuso's presentation will be available by live webcast streaming online and archived for 90 days.
To access the webcast, go to http://wsw.com/webcast/marcum5/rspi or visit the RespireRx website at www.respirerx.com, click on the same link on the home page, or, click on the Investors tab and follow the links to this press release and click the webcast link.
Be sure to subscribe to one or more of our free newsletters so you never miss an important update. If you haven't already, connect with The Daily Marijuana Observer on Facebook, Twitter, and Instagram.